NCT00966368View on ClinicalTrials.gov

Comparison of Two NN1250 Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
DiabetesHealthy
Interventions
DRUG

insulin degludec

Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)

DRUG

insulin degludec

Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)

Trial Locations (1)

91911-1350

Novo Nordisk Clinical Trial Call Center, Chula Vista

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY